Wire · operational-macro
South Africa's Aspen Pharmacare to sell women's health product in Europe to Ennogen
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
South Africa’s Aspen Pharmacare is selling the European commercialisation rights and related intellectual property for its women’s health product Ovestin to Ennogen Healthcare International for €197 million, with long-term supply and support agreements included.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 2 Nov 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You need to reassess your market focus if you supply women’s health products in Europe as Aspen’s move shows manufacturers can monetise non-core assets while retaining contracts. This deal opens a sales channel through Ennogen but means you face a new player handling commercialisation in key European markets.
◆ Coverage
2 sources · first reported 2 Nov 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics